HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High SPF "Uses" Labeling Statement Addresses FDA Concerns - CTFA

This article was originally published in The Rose Sheet

Executive Summary

Sunscreens with SPF values over 30 should carry a mandatory labeling statement that advises consumers against extending the length of time spent in the sun while noting the benefits of additional sun protection, the Cosmetic, Toiletry and Fragrance Association suggests in May 25 comments to FDA.

You may also be interested in...



Sunscreen, OTC Labeling Reg First Amendment Intrusions Cited By CTFA

FDA's sunscreen and OTC labeling final regs will have difficulty passing constitutional muster in light of a recent court decision requiring agency-drafted disclaimers for a folic acid health claim, the Cosmetic, Toiletry and Fragrance Association maintains.

Sunscreen, OTC Labeling Reg First Amendment Intrusions Cited By CTFA

FDA's sunscreen and OTC labeling final regs will have difficulty passing constitutional muster in light of a recent court decision requiring agency-drafted disclaimers for a folic acid health claim, the Cosmetic, Toiletry and Fragrance Association maintains.

High SPF Sunscreen Additional Data Sought By FDA

FDA expects to publish a "comprehensive" sunscreen final monograph covering formulation, labeling and testing methodologies for both UVA and UVB radiation by Dec. 31, 2001, the agency announced in a June 8 Federal Register notice.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel